Therachon Acquires GLyPharma Therapeutic to Expand its Rare Disease Portfolio

 Therachon Acquires GLyPharma Therapeutic to Expand its Rare Disease Portfolio

Therachon Acquires GLyPharma Therapeutic to Expand its Rare Disease Portfolio

Shots:

  • Therachon gains exclusive commercialization and development rights to apraglutide, initially developed by Ferring Pharma and was exclusively licensed by GLyPharma in 2012. Novo Holdings to fund the transaction with $60M
  • The focus of the agreement is to improve QoL by providing novel and efficacious therapies for rare conditions including short bowel syndrome(SBS) and rare gastrointestinal diseases
  • Apraglutide (FE 203799) is a qw synthetic GLP-2 analog, completed its P-I clinical trial demonstrated superior PK and currently evaluated in P-II for SBS

Click here to read full press release/ article | Ref: Therachon| Image: Sustain Ability

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post